For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

“These therapies provide the first new classes of medications approved for COPD in nearly 20 years,” said David M. Mannino, MD, of the University of Kentucky, Lexington, Kentucky, in an interview.

TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients in the United States free of charge. “In the United ...

data from the MATINEE study to support the regulatory review process to obtain a new indication for the use of Nucala (mepolizumab) in chronic obstructive pulmonary disease or COPD. The submission ...

Eligible patients had COPD, were ages 40 or older, and were new initiators of these inhalers from 2021 to 2023. They were allowed to be on monotherapy or dual therapy during the year before cohort ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...